Dr Lee Smith is a Director, Managing Partner, and the founder of GreyRigge Associates (GRA). He focuses on three critical strategic areas: transitioning complex novel therapeutics through early- and late-stage product lifecycles, navigating international regulatory agency frameworks, and optimising commercialisation paths for biopharmaceutical developers. Having founded GRA in 2010 following extensive executive-level tenure as a CEO and VP, Lee bridges the gap between high-level laboratory science and commercial asset delivery. He holds a PhD in Biochemistry from the University of Bath, United Kingdom.
Expertise: Primary Service Skillsets
CMC & Manufacturing Oversight
Lee possesses deep practical expertise across the technical design, manufacturing scale-up, and analytical characterisation of diverse biopharmaceutical modalities. His technical skillset focuses on embedding structured, science-driven architectures into active development pipelines.
- Modality Depth: Comprehensive technical oversight spanning monoclonal antibodies, cell and gene therapies (CGT), oncology, and infectious diseases.
- Vaccine Platforms: Directing technical and process paths for more than 20 developmental vaccines.
- QbD Implementation: Performing global training and operational delivery of Quality by Design (QbD) methodologies, process validation, and analytical development workflows.
QA, Auditing & Regulatory Affairs
His regulatory expertise centres on translating complex laboratory datasets into approvable, high-quality dossiers that meet the shifting compliance thresholds of global governing bodies.
- Dossier Mastery: Authoring and restructuring regulatory documentation, including Biologics License Applications (BLAs) and clinical trial submissions.
- Agency Engagement: Directing scientific advice briefings and critical regulatory interactions with senior reviewers at the FDA, EMA, and MHRA.
- Compliance Standards: Building and auditing Quality Management Systems across GxP, HACCP, and ISO frameworks to comply with European, American, and ASEAN requirements.
Strategic Planning & Due Diligence
Lee provides high-level corporate and commercial guidance to align business growth with technical execution, protecting intellectual property and maximising asset value.
- Commercialisation & BD: Structuring in-licensing strategies, operational adjustments, and patent filing pathways to improve top- and bottom-line commercial metrics.
- Executive Leadership: Managing complete board activities, P&L allocation, corporate balance sheets, and client fundraising readiness as an Interim CEO and Executive Consultant.
Additional Technical Specialisms
To ensure comprehensive support across the full development lifecycle, Lee also provides expert consultancy across these core GRA service areas:
- CDMO & CRO Network Management: Managing complex technical collaborations and technology transfers across an extensive international network of CDMOs, CROs, academic partners, and non-governmental organisations (NGOs).
- Assays & QC Validation: Applying hands-on biopharmaceutical experience across R&D, analytical characterisation, and release testing for early- and late-stage biologics.
- Formulation Development: Guiding phase-appropriate formulation strategies to enhance product stability and delivery across diverse indications.
- Clinical Project Management: Leading cross-functional project teams to ensure forward momentum, rigorous risk management, and value creation throughout Phase I–III clinical trials.
To understand more about Lee and his background, click here.
If you would like to discuss your project with Dr Lee Smith or require specialist advice please get in touch.
